目的研究血管紧张素转换酶抑制剂(acei)和血管紧张素受体拮抗剂(arb)对2型糖尿病肾病患者肾功能的保护作用。
Objective to investigate the protective effect of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor antagonist (ARB) on renal function of type 2 diabetic nephropathy patients.
血管紧张素转化酶抑制剂和血管紧张素受体拮抗剂联合用药治疗CKD是否比单药应用要好？
Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination therapy Better Than Monotherapy and Safe in Patients With CKD?
EGFR和VEGFR途径拮抗剂在治疗转移性NSCLC中的成功对开发一种新的靶向治疗药物如PKC抑制剂具有重要意义。
The success of the EGFR and VEGFR pathway antagonists in treatment of metastatic NSCLC has important implications for development of novel targeted therapies such as the PKC inhibitors.
结果：ace抑制剂和钙离子拮抗剂是临床应用最多的抗高血压药，两者占抗高血压药物使用金额的78.3%。结论：卡托普利和尼群地平是抗高血压常用药。
Our results showed that ACE inhibitors and calcium blockers were most commonly used antihypertensive agents, and the two agents accounted for 78.3% of all antihypertensives in terms of sales amount.
本发明涉及某些喹啉化合物，其用作神经激肽- 1 (NK - 1)受体拮抗剂，和速激肽及特别是P物质抑制剂。
The present invention is directed to certain quinoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance p.
本发明涉及某些喹啉化合物，其用作神经激肽- 1 (NK - 1)受体拮抗剂，和速激肽及特别是P物质抑制剂。
The present invention is directed to certain quinoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance p.
应用推荐